O	0	10	Randomized
O	11	17	Double
O	17	18	-
O	18	23	blind
O	24	31	Placebo
O	31	32	-
O	32	42	controlled
O	43	48	Trial
O	49	51	of
B-intervention	52	61	Celecoxib
O	62	65	for
O	66	69	the
O	70	80	Prevention
O	81	83	of
B-condition	84	88	Skin
I-condition	89	97	Toxicity
O	98	100	in
O	101	109	Patients
O	110	119	Receiving
O	120	129	Radiation
O	130	137	Therapy
O	138	141	for
O	142	148	Breast
O	149	155	Cancer
O	155	156	.

O	157	160	The
O	161	165	skin
O	166	174	toxicity
O	174	175	-
O	175	182	induced
O	183	185	by
O	186	194	ionizing
O	195	204	radiation
O	205	208	may
O	209	214	limit
O	215	218	the
O	219	227	duration
O	228	230	of
O	231	240	treatment
O	241	244	and
O	245	248	may
O	249	253	lead
O	254	256	to
O	257	267	discomfort
O	268	270	in
O	271	278	quality
O	279	281	of
O	282	286	life
O	287	289	of
O	290	298	patients
O	299	305	during
O	306	318	radiotherapy
O	318	319	.

O	320	323	The
O	324	331	purpose
O	332	334	of
O	335	339	this
O	340	350	randomized
O	350	351	,
O	352	359	placebo
O	359	360	-
O	360	370	controlled
O	370	371	,
O	372	378	double
O	378	379	-
O	379	384	blind
O	385	390	study
O	391	394	was
O	395	397	to
O	398	409	investigate
O	410	413	the
O	414	424	preventive
O	425	431	effect
O	432	434	of
O	435	439	oral
O	440	454	administration
O	455	457	of
O	458	467	celecoxib
O	468	469	(
O	469	472	CLX
O	472	473	)
O	474	476	on
O	477	480	the
O	481	486	acute
O	487	496	radiation
O	496	497	-
O	498	505	induced
O	506	510	skin
O	511	519	toxicity
O	520	522	in
B-eligibility	523	531	patients
I-eligibility	532	536	with
I-eligibility	537	543	breast
I-eligibility	544	550	cancer
O	550	551	.

B-total-participants	552	557	Sixty
O	558	564	breast
O	565	571	cancer
O	572	580	patients
O	581	585	were
O	586	594	randomly
O	595	603	assigned
O	604	606	to
O	607	610	use
O	611	614	CLX
O	615	616	(
O	616	619	400
O	620	622	mg
O	623	626	per
O	627	630	day
O	630	631	)
O	632	634	or
B-control	635	642	placebo
O	643	651	capsules
O	652	658	during
O	659	671	radiotherapy
O	671	672	.

O	673	682	Radiation
O	682	683	-
O	683	690	induced
O	691	701	dermatitis
O	702	705	was
O	706	716	classified
O	717	726	according
O	727	729	to
O	730	733	the
O	734	743	radiation
O	744	751	therapy
O	752	760	oncology
O	761	766	group
O	767	768	(
O	768	772	RTOG
O	772	773	)
O	774	782	criteria
O	782	783	,
O	784	786	as
O	787	791	well
O	792	794	as
O	795	799	pain
O	800	803	and
O	804	811	itching
O	812	816	were
O	817	823	scored
O	824	833	according
O	834	836	to
O	837	840	the
O	841	844	VAS
O	845	846	(
O	846	852	Visual
O	853	861	Analogue
O	862	867	Scale
O	867	868	)
O	869	872	for
O	873	876	six
O	877	882	weeks
O	883	885	of
O	886	895	treatment
O	895	896	.

O	897	903	Breast
O	904	912	swelling
O	913	916	was
O	917	926	evaluated
O	927	934	through
O	935	943	increase
O	944	946	in
O	947	950	the
O	951	955	size
O	956	958	of
O	959	962	the
O	963	969	breast
O	970	976	during
O	977	989	radiotherapy
O	989	990	.

O	991	995	Oral
O	996	1010	administration
O	1011	1013	of
O	1014	1017	CLX
O	1018	1025	capsule
O	1026	1032	during
O	1033	1036	and
O	1037	1042	after
O	1043	1055	radiotherapy
O	1056	1063	reduced
O	1064	1077	significantly
B-outcome	1078	1087	radiation
I-outcome	1087	1088	-
I-outcome	1088	1095	induced
I-outcome	1096	1103	itching
I-outcome	1104	1107	and
I-outcome	1108	1112	pain
O	1113	1115	in
O	1116	1124	patients
O	1125	1129	with
O	1130	1136	breast
O	1137	1143	cancer
O	1143	1144	.

O	1145	1148	CLX
O	1149	1156	reduced
O	1157	1160	the
B-outcome	1161	1170	frequency
I-outcome	1171	1173	of
I-outcome	1174	1183	increased
I-outcome	1184	1190	breast
I-outcome	1191	1195	size
O	1196	1202	caused
O	1203	1205	by
O	1206	1218	radiotherapy
O	1219	1221	in
O	1222	1230	patients
O	1231	1233	as
O	1234	1242	compared
O	1243	1247	with
O	1248	1255	placebo
O	1255	1256	;
O	1257	1264	however
O	1264	1265	,
O	1266	1270	this
O	1271	1281	difference
O	1282	1285	was
O	1286	1299	statistically
O	1300	1303	not
O	1304	1315	significant
O	1315	1316	.

O	1317	1325	Patients
O	1326	1329	who
O	1330	1338	received
O	1339	1342	CLX
O	1343	1346	had
O	1347	1362	insignificantly
B-outcome	1363	1367	skin
I-outcome	1368	1378	dermatitis
O	1379	1383	when
O	1384	1392	compared
O	1393	1397	with
O	1398	1405	placebo
O	1406	1411	group
O	1411	1412	.

O	1413	1420	However
O	1420	1421	,
O	1422	1425	CLX
O	1426	1429	was
O	1430	1436	unable
O	1437	1439	to
O	1440	1446	reduce
O	1447	1450	the
B-outcome	1451	1461	dermatitis
O	1462	1468	caused
O	1469	1471	by
O	1472	1480	ionizing
O	1481	1490	radiation
O	1490	1491	;
O	1492	1494	it
O	1495	1508	significantly
O	1509	1516	reduced
B-outcome	1517	1524	itching
I-outcome	1525	1528	and
I-outcome	1529	1533	pain
O	1534	1536	in
O	1537	1545	patients
O	1546	1552	during
O	1553	1565	radiotherapy
O	1565	1566	.

O	1567	1570	CLX
O	1571	1574	may
O	1575	1579	have
O	1580	1590	beneficial
O	1591	1598	effects
O	1599	1601	in
O	1602	1605	the
O	1606	1613	quality
O	1614	1618	life
O	1619	1621	of
O	1622	1628	breast
O	1629	1635	cancer
O	1636	1644	patients
O	1645	1648	for
O	1649	1658	treatment
O	1658	1659	.
